This session discusses moving beyond GLP-1 RA therapy for drug developers. It will begin with an overview of current GLP 1 RA applications and a discussion of outcomes reported patients treated with GLP-1s. The session will then examine key considerations for developing next generation metabolic therapies, supported by examples from recent drug development programs.